AbbVie Inc. (ABBV)
NYSE: ABBV · IEX Real-Time Price · USD
185.16
+2.99 (1.64%)
At close: Jul 26, 2024, 4:00 PM
185.07
-0.09 (-0.05%)
After-hours: Jul 26, 2024, 7:58 PM EDT
AbbVie Revenue
AbbVie had revenue of $14.46B in the quarter ending June 30, 2024, with 4.31% growth. This brings the company's revenue in the last twelve months to $55.00B, down -1.83% year-over-year. In the year 2023, AbbVie had annual revenue of $54.32B, down -6.44%.
Revenue (ttm)
$55.00B
Revenue Growth
-1.83%
P/S Ratio
6.01
Revenue / Employee
$1,088,060
Employees
50,000
Market Cap
326.97B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 54.32B | -3.74B | -6.44% |
Dec 31, 2022 | 58.05B | 1.86B | 3.30% |
Dec 31, 2021 | 56.20B | 10.39B | 22.69% |
Dec 31, 2020 | 45.80B | 12.54B | 37.69% |
Dec 31, 2019 | 33.27B | 513.00M | 1.57% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 379.49B |
Johnson & Johnson | 81.80B |
Merck & Co. | 61.40B |
AstraZeneca | 49.13B |
Novartis AG | 48.86B |
Thermo Fisher | 42.49B |
Abbott Laboratories | 40.33B |
Eli Lilly | 35.93B |
ABBV News
- 5 hours ago - AbbVie Wins Analyst Confidence with Q2 Beat, Diverse Portfolio Fuels Long-Term Growth Expectations - Benzinga
- 18 hours ago - AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis - PRNewsWire
- 1 day ago - AbbVie Stock Hits Record High on Demand for Non-Humira Portfolio - Investopedia
- 1 day ago - AbbVie's Q2 Earnings Beat Estimates, Raises Annual Profit On Strong Sales From Newer Immunology And Cancer Drugs - Benzinga
- 1 day ago - AbbVie Stock Is Rising on Strong Earnings. CEO Cites ‘Significant Momentum. - Barrons
- 1 day ago - AbbVie lifts annual profit forecast on strong immunology drug sales - Reuters
- 1 day ago - AbbVie's quarterly results top estimates as newer drugs cushion Humira's slide - Market Watch
- 1 day ago - AbbVie Reports Second-Quarter 2024 Financial Results - PRNewsWire